Recombinant Human Prourokinase for Injection (rhPro-UK)

DRUG2 trials

Sponsors

Beijing Tiantan Hospital, The First Affiliated Hospital of Anhui Medical University

Conditions

Acute Ischemic StrokeIschemic StrokeMildThrombosis

Phase 3

ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)

CompletedNCT05507645

Beijing Tiantan HospitalIschemic Stroke, Mild, Thrombosis

Start: 2022-11-15End: 2024-06-17Updated: 2024-09-05

Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke

Not yet recruitingNCT07776873

The First Affiliated Hospital of Anhui Medical UniversityAcute Ischemic Stroke

Start: 2026-09-06End: 2029-06-30Target: 616Updated: 2026-08-20

Related Papers

Prourokinase vs Standard Care for Patients With Mild Ischemic Stroke

JAMA Neurology2025-01-2115 citations

Rationale and design of ProUrokinase in Mild IsChemic strokE (PUMICE): a multicentre, prospective, randomised, open-label, blinded-endpoint controlled trial.

2024-12-303 citations